Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ease type a plus sign (+) inside this box ightarrow 1+Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 09/312,351 Application Number TRANSMITTAL 5/14/99 Filing Date RECEIVED Wolff FORM **First Named Inventor** NOV 26 1999 1621 **Group Art Unit** (to be used for all correspondence after initial filing) TECH CENTER 16 00/2900 **Examiner Name** Mirus.006.01 1 Attorney Docket Number Total Number of Pages in This Submission ENCLOSURES (check all that apply) After Allowance Communication **Assignment Papers** Fee Transmittal Form (for an Application) to Group **Appeal Communication to Board** Fee Attached Drawing(s) of Appeals and Interferences Appeal Communication to Group Amendment / Response Licensing-related Papers (Appeal Notice, Brief, Reply Brief) Petition Routing Slip_(PTO/SB/69) After Final **Proprietary Information** and Accompanying Petition Petition to Convert to a Affidavits/declaration(s) Status Letter **Provisional Application** Power of Attorney, Revocation Change of Correspondence Additional Enclosure(s) Extension of Time Request (please identify below): Address Terminal Disclaimer **Express Abandonment Request Small Entity Statement** Information Disclosure Statement Request for Refund Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Mark K. Johnson Individual name Signature

> **CERTIFICATE OF MAILING** I hereby certify that this correspondence is being deposited with the United States Postal Service as<u>express mail in an</u> envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: November 22, 1999 Mark K. Johnson Date November 22, 1999

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you errequired to complete this form should be send to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

November 22, 199

Date

Typed or printed name

Signature

Application of: Jon A. Wolff,)
Sean D. Monahan, David B. Rozema,)
Paul M. Slattum, and Vladimir Budker)
)
Serial No.: 08/312,351)
)
Filed: 5/14/99)

For: A Compound Containing a Labile Disulfide Bond

INFORMATIONAL STATEMENT

Commissioner of Patents and Trademarks Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. 1.56, applicant hereby calls to the attention of the Patent and Trademark Office the publications listed on the attached PTO 1449. One copy of each publication is attached.

UNITED STATES PATENTS

Patent No. Inventor Issue Date

FOREIGN PATENTS

Patent No. Inventor Issue Date

REFERENCES CITED

Arpicco, S. Et al., "New Coupling Reagents for the Preparation of Disulfide Cross-Linked Conjugates with Increased Stability." <u>Dipartimento di Scienza e Tecnologia Del Farmaco, V.P. Giuria 9</u> September 30 1996.

Bulaj, G. Et al., "Ionization-Reactivity Relationships for Cysteine Thiols in Polypeptides." Biochemistry 1998; 37; 8905-8972.

Keire, D. Et al., "Kinetics and Equilibria of Thiol/Disulfide Interchange Reactions of Selected Biological Thiols and Related Molecules with Oxidized Glutathione." J. Org. Chem. 1992; 57; 123-127.

Kishore, K. Et al., "Polymers Containing Disulfide, Tetrasulfide, Diselenide and Ditelluride Linkages in the Main Chain." Advances in Polymer Sciences 1995; Vol. 121; 83-117.

Lee, R., Et al., "Folate-mediated Tumor Cell Targeting of Liposome-Entrapped Doxorubicin in Vitro." Biochimica et Biophysica Acta 1995; 1233; 134-144.

Szajewski, R. Et al., "Rate Constants and Equilibrium Constants for Thiol-Disulfide Interchange Reactions Involving Oxidized Glutathione." Journal of the American Chemical Society March 12, 1980; 102:6; 2011-2025.

Thorpe, P. Et al., "Comparison of Two Anti-Thy 1.1-Abrin A-Chain Immunotoxins Prepared With Different Cross-Linking Agents: Antitumor Effects, In Vivo Fate, and Tumor Cell Mutants." JNCI November 1987; Vol. 79 No. 5; 1101-1112.

Trubetskoy, V. Et al., "Quantitative Assessment of DNA Condensation." Analytical Biochemistry 1999; 267; 309-313.

Wolff, J. Et al., "Direct Gene Transfer into Mouse Muscle in Vivo." Science March 1990; 247; 1465-1468.

Applicant respectfully requests that these publications be expressly considered during the prosecution of this application and made of record herein and appear among the 'References Cited' on any patent to issue herefrom.

Respectfully submitted,

Mark K. Johnson Reg. No. 35,909

P.O. Box 510644

New Berlin, WI 53151-0644

(414) 821-5690

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to: Commissioner of Patents and Trademarks

Washington, D.C. 20231 on

Date of Signature

Silenature